Olema Pharmaceuticals (OLMA) Competitors $6.35 +0.06 (+0.95%) Closing price 04:00 PM EasternExtended Trading$6.28 -0.07 (-1.04%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OLMA vs. HROW, SDGR, AVDL, AMPH, SNDX, VERA, COGT, JANX, PGEN, and ETNBShould you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include Harrow (HROW), Schrodinger (SDGR), Avadel Pharmaceuticals (AVDL), Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), Vera Therapeutics (VERA), Cogent Biosciences (COGT), Janux Therapeutics (JANX), Precigen (PGEN), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. Olema Pharmaceuticals vs. Its Competitors Harrow Schrodinger Avadel Pharmaceuticals Amphastar Pharmaceuticals Syndax Pharmaceuticals Vera Therapeutics Cogent Biosciences Janux Therapeutics Precigen 89BIO Olema Pharmaceuticals (NASDAQ:OLMA) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings. Which has more volatility & risk, OLMA or HROW? Olema Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Which has preferable earnings and valuation, OLMA or HROW? Harrow has higher revenue and earnings than Olema Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOlema PharmaceuticalsN/AN/A-$129.47M-$1.98-3.21Harrow$199.61M6.71-$17.48M-$0.25-144.80 Do insiders and institutionals have more ownership in OLMA or HROW? 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 16.4% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 15.2% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor OLMA or HROW? In the previous week, Olema Pharmaceuticals had 3 more articles in the media than Harrow. MarketBeat recorded 8 mentions for Olema Pharmaceuticals and 5 mentions for Harrow. Harrow's average media sentiment score of 1.33 beat Olema Pharmaceuticals' score of 0.96 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer OLMA or HROW? Olema Pharmaceuticals presently has a consensus price target of $24.00, suggesting a potential upside of 277.95%. Harrow has a consensus price target of $64.67, suggesting a potential upside of 78.64%. Given Olema Pharmaceuticals' higher probable upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Olema Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is OLMA or HROW more profitable? Olema Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -4.49%. Harrow's return on equity of -2.18% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Olema PharmaceuticalsN/A -42.58% -38.65% Harrow -4.49%-2.18%-0.35% SummaryHarrow beats Olema Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OLMA vs. The Competition Export to ExcelMetricOlema PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$431.71M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-3.2120.8978.4326.42Price / SalesN/A458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book0.899.9310.916.06Net Income-$129.47M-$53.38M$3.29B$266.28M7 Day Performance15.04%0.05%0.01%-0.76%1 Month Performance17.38%7.08%7.06%3.83%1 Year Performance-44.54%11.92%50.09%24.39% Olema Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OLMAOlema Pharmaceuticals2.4732 of 5 stars$6.35+1.0%$24.00+278.0%-44.6%$431.71MN/A-3.2170News CoverageAnalyst ForecastHigh Trading VolumeHROWHarrow3.557 of 5 stars$39.00+0.0%$64.67+65.8%-5.8%$1.44B$199.61M-156.00180SDGRSchrodinger2.8823 of 5 stars$19.51-1.3%$27.83+42.7%-6.1%$1.44B$207.54M-7.87790Positive NewsAVDLAvadel Pharmaceuticals3.7447 of 5 stars$14.76+1.0%$19.67+33.2%-2.1%$1.43B$169.12M-492.0070Trending NewsAnalyst ForecastAnalyst RevisionAMPHAmphastar Pharmaceuticals3.4145 of 5 stars$30.62+1.2%$31.60+3.2%-37.4%$1.42B$731.97M11.472,028Positive NewsSNDXSyndax Pharmaceuticals4.4477 of 5 stars$16.33+0.1%$38.00+132.7%-21.5%$1.41B$23.68M-4.20110News CoveragePositive NewsAnalyst ForecastVERAVera Therapeutics2.8807 of 5 stars$21.64-2.9%$63.00+191.1%-40.1%$1.38BN/A-6.0440News CoveragePositive NewsCOGTCogent Biosciences3.1707 of 5 stars$12.08flat$19.00+57.3%+19.5%$1.38BN/A-6.7980News CoveragePositive NewsAnalyst ForecastJANXJanux Therapeutics2.6833 of 5 stars$22.72-1.4%$86.90+282.5%-48.8%$1.37B$10.59M-12.6230News CoveragePositive NewsAnalyst ForecastPGENPrecigen4.2938 of 5 stars$4.51-0.9%$8.25+82.9%+348.1%$1.34B$3.92M-10.74190ETNB89BIO2.6109 of 5 stars$9.03-4.1%$26.63+194.9%+5.2%$1.34BN/A-2.5040News CoverageAnalyst Forecast Related Companies and Tools Related Companies HROW Alternatives SDGR Alternatives AVDL Alternatives AMPH Alternatives SNDX Alternatives VERA Alternatives COGT Alternatives JANX Alternatives PGEN Alternatives ETNB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OLMA) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredNewegg (NEGG) Earns BULLISH Rating – Up 934%The last time he shared a free AI stock pick like this, it soared 100%.Chaikin Analytics | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OLMA Stock Alerts